Antibody Response Post-COVID-19 Vaccination in Patients With Chronic Myeloid Leukemia With Comparison Between Comirnaty and CoronaVac Vaccine

Kuan JW Melaine Michael S . The epidemiology of chronic myeloid leukaemia in southern Sarawak, Borneo Island. Med J Malaysia. 2018;73(2):78-85.

Chowdhury O Bruguier H Mallett G , et al. Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms. Br J Haematol. 2021;194(6):1010-1015. doi:10.1111/bjh.17644.

Harrington P Doores KJ Radia D , et al. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. Br J Haematol. 2021;194(6):999-1006. doi:10.1111/bjh.17568.

Kuan JW Chang KM Phan CL , et al. Fluctuation of BCR-ABL1 qPCR(IS) level beyond 0.1%(IS) after stopping tyrosine kinase inhibitor in chronic myeloid leukaemia patients with deep molecular response for at least two years. Med J Malaysia. 2021;76(3):414-416.

U.S. Food & Drug Administration. FDA in brief: FDA updates emergency use authorization for COVID-19 convalescent plasma to reflect new data; 2020. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-updates-emergency-use-authorization-covid-19-convalescent-plasma-reflect-new-data?utm_medium=email&utm_source=govdelivery.